BOLERO-2 - will this change practice in advanced breast cancer?

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Johnston, Stephen R D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; EVEROLIMUS; EXEMESTANE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TEMSIROLIMUS; TRASTUZUMAB; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RELAPSE; CLINICAL PRACTICE; DISEASE COURSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HEALTH CARE QUALITY; HORMONE SENSITIVITY; HUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS; ARTICLE; BREAST TUMOR; DRUG ANTAGONISM;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84862494067     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3126     Document Type: Note

References (15)

1. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11:643-658. 10.1677/erc.1.00776, 15613444.
2. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomised placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive advanced breast cancer: results form EFECT. J Clin Oncol 2008, 26:1664-1670. 10.1200/JCO.2007.13.5822, 18316794.
3. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278:30458-30468. 10.1074/jbc.M305226200, 12775708.
4. Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999, 6:373-387. 10.1677/erc.0.0060373, 10516852.
5. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824. 10.1074/jbc.M010840200, 11139588.
6. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neo-adjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822. 10.1200/JCO.2006.09.6578, 17679728.
7. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17:1147-1159. 10.1158/1078-0432.CCR-10-1869, 3074404, 21220480.
8. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16:1904-1914. 10.1158/1078-0432.CCR-09-2282, 20215537.
9. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5846. 10.1200/JCO.2009.23.3734, 19786658.
10. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results form the randomized TAnDEM study. J Clin Oncol 2009, 27:5529-5537. 10.1200/JCO.2008.20.6847, 19786670.
11. Baselga J, Campone M, Piccart M, Burris HA 3, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
12. Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, Eymard J-C, Debled M, Spaeth D, Legouffe E, Delozier T, El Kouri C, Chidiac J. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 2010, 70(Suppl 2). Abstract S1-6.
13. CChow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl 1). Abs 6091.
14. Sabnis G, Schavowitz A, Goloubeva O, Macedo LF, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009, 69:1416-1428. 10.1158/0008-5472.CAN-08-0857, 2644349, 19190349.
15. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomised study of neo-adjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637. 10.1200/JCO.2008.18.8391, 19380449.